Links

Homepage

Stock List

Search by Ticker

News

Login

Abiomed (NASDAQ:ABMD)
Stock Analysis

ABMD294.87
▼ -1.72%-5.15

Stock Analysis

The following stock analysis is based on 7.8 years of data (i.e. since Oct 31, 2012). All the stock history has been downloaded.

Stock Exchange

Abiomed trades on the NasdaqGS exchange in USD dollars.

Sector

It is in the healthcare sector.

Current Status of Abiomed

It is currently trading at $294.87 ($300.02 the previous day).

Financials

The next reporting date is in 78 days (2020 10 29).

CNN estimates profits for the upcoming quarter will be $0.99 per share ($202.9M). The current Canada / US exchange rate is 1.3303.



Over the past 12 months, $0 worth of shares have been purchased and $7377059 worth of shares have been sold by insiders.

Will This Trend Continue?

The year over year average increase is 26.6% per year assuming steady exponential growth. The actual 5 year average is 43.5. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year191.44450215054-41.2- Below Average
2 year325.5575486486519.6- Below Average
3 year272.1759832636115.7+ Above Average
4 year126.1679268292732.4- Below Average
5 year95.31464150943491+ Above Average
Abiomed is projected by analysts to get to $350.00 within the next 12 months (18.7%), but preticted targets range from as high as $365.00 (23.8%) and as low as $217(-26.4%).

Risk

The worst drop it has had in recent years is -71.0%. It has a dropping shape to the stock curve, which means the stock has to be watched closely. If the financials are good, it could be very profitable, however if not it may not recover and should be sold.

Stock shape test

DAYS AG0PRICE
10298.61DROPPING
30264.59RISING
60253.3RISING
150163.185RISING
365203.9008DROPPING
800392.25DROPPING
1200130.92RISING
160091.54RISING
200060.62RISING


With an average increase of 26.6% year over year, if Abiomed is bought at the worst time, Stockmarketizer analysts estimate it will take 32 months before the stock will recover to the original purchase price. The P/E value is 84.9. The stock is under valued as the industry standard in the healthcare sector is a P/E of 86.26.

Description

Abiomed is a manufacturer of medical implant devices, including the AbioCor artificial heart and Impella. For example, they acquired Impella technology in 2005 and have since received a series of FDA approvals. Overall, Abiomed engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients.

It's main office is located in Danvers, Massachusetts. There are three additional offices located in Germany (Berlin and Aachen) and Japan. The CEO is Michael R. Minogue, who joined Abiomed in 2004.

They have invested more than $100 million over the past five years in clinical research on the Impella heart pump platform. They have one of the most complete and extensive post-market surveillance programs in the medical device industry, that includes the Impella Quality Assurance (IQ) Database, the FDA-audited cVAD Study, and real-time monitoring of patients on Impella support through industry-leading 24x7 clinical support services.

Additionally, Abiomed plans to continue to actively support clinical research, including two randomized controlled trials, in 2019 that include:

  • STEMI-DTU pivotal randomized controlled trial, which will compare unloading the left ventricle with Impella to the current standard of care.
  • The ongoing Dan-Ger Shock randomized control trial for cardiogenic shock.
  • Ongoing data collection, monitoring and analysis for the IQ Database, cVAD Study and five FDA post-market studies.

Tradingview BuySell Widget

Yahoo News Feed

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q1

Thu, 06 Aug 2020 13:26:01 ABIOMEDand's (ABMD) flagship Impella saw decline in revenues internationally and within the United States, in Q1.... Read Full Article

Abiomed (ABMD) Tops Q1 Earnings and Revenue Estimates

Thu, 06 Aug 2020 12:25:12 Abiomed (ABMD) delivered earnings and revenue surprises of 176.19% and 19.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?... Read Full Article

Abiomed Announces Q1 FY 2021 Revenue of $165 Million and 21% Operating Margin

Thu, 06 Aug 2020 11:00:00 Abiomed announces Q1 FY 2021 revenue of $165 million and 21% operating margin.... Read Full Article

ABIOMED (ABMD) to Report Q1 Earnings: Whatand's in the Offing?

Tue, 04 Aug 2020 12:50:12 The commercial rollout of ABIOMEDand's (ABMD) Impella 5.5 is expected to have progressed steadily through the fiscal first quarter.... Read Full Article

Abiomed’s Impella Scores Emergency FDA Nod For Covid-19 Patients

Tue, 04 Aug 2020 12:39:18 Abiomed (ABMD) has announced that the US Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 patients who are undergoing ECMO treatment and ...... Read Full Article

Abiomed heart pump gets second FDA emergency use nod for COVID-19 patients

Tue, 04 Aug 2020 12:05:34 Medical device maker Abiomed Inc said on Tuesday the U.S. Food and Drug Administration granted its left-sided heart pumps emergency use authorization to help patients suffering from COVID-19-related heart and lung failures. COVID-19, the respiratory disease caused by ...... Read Full Article

Abiomedand's stock rises on second COVID-19-related EUA for heart pump

Tue, 04 Aug 2020 11:48:00 Shares of Abiomed Inc. rallied 2.0% in premarket trading on Tuesday after the company said its Impella heart pump had received an emergency use authorization from the Food and Drug Administration as a treatment for some COVID-19 patients. The heart pump ...... Read Full Article

FDA Issues Emergency Use Authorization for Impella Heart Pumps to Provide Unloading Therapy to COVID-19 Patients

Tue, 04 Aug 2020 11:00:00 The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 patients who are undergoing ECMO treatment and develop pulmonary edema or ...... Read Full Article

How Much Is Abiomed, Inc. (NASDAQ:ABMD) Paying Its CEO?

Fri, 31 Jul 2020 12:02:25 This article will reflect on the compensation paid to Mike Minogue who has served as CEO of Abiomed, Inc...... Read Full Article

Large Multi-Center Study in Japan Finds High Survival Rates with Use of Impella Heart Pump

Thu, 30 Jul 2020 12:00:00 A three-year, investigator-led, prospective study of Japanese patients who received an Impella heart pump finds use of Impella is associated with a 77% survival rate at 30 days in AMI cardiogenic shock patients. The historic survival rate for cardiogenic shock is approximately 50%. ...... Read Full Article

FMS vs. ABMD: Which Stock Should Value Investors Buy Now?

Wed, 22 Jul 2020 15:40:03 FMS vs. ABMD: Which Stock Is the Better Value Option?... Read Full Article

Abiomed Gets FDA Nod for Data Streaming Via Impella Connect

Mon, 20 Jul 2020 12:19:12 Abiomedand's (ABMD) announcement of the FDA approval of one-way digital data streaming from the Impella Connect interface can boost patient outcomes further.... Read Full Article

Abiomed First Quarter Fiscal 2021 Earnings and Conference Call Notification

Thu, 16 Jul 2020 11:00:00 Abiomed announced that on Thursday, August 6, 2020, the Company will release financial results for the first quarter of fiscal 2021.... Read Full Article

FDA Approves Data Streaming from the Impella Console, Setting the Stage for Artificial Intelligence Algorithms to Further Improve Patient Outcomes

Thu, 16 Jul 2020 11:00:00 The United States Food and Drug Administration (FDA) has approved one-way digital data streaming during patient support from Abiomedand's (NASDAQ: ABMD) Automated Impella Controller (AIC), the external console used with Impella heart pumps. The data streaming capability is facilitated through ...... Read Full Article

Did Hedge Funds Make The Right Call On ABIOMED, Inc. (ABMD) ?

Sun, 12 Jul 2020 23:38:17 The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge ...... Read Full Article

Are These Medical Stocks Cruising Toward Big Gains? Hereand's A Bullish Sign

Thu, 09 Jul 2020 14:00:26 Medical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth.... Read Full Article

MiMedx Announces Concurrent $150 Million Private Equity and Debt Financings

Thu, 02 Jul 2020 13:00:10 MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the closing of concurrent $150 million private equity and debt financings, consisting of an equity financing ...... Read Full Article

Study Finds 84% Survival Rate in Patients in Cardiogenic Shock and Other Challenging Cardiac Conditions with the New Impella 5.5 with SmartAssist

Wed, 01 Jul 2020 11:00:00 The first published United States experience of patients who received Abiomed’s newest heart pump, Impella 5.5 with SmartAssist, finds 84% of the patients survived to explant with 76% native heart recovery. The study was published in the July edition of the American ...... Read Full Article

Edited Transcript of ABMD earnings conference call or presentation 30-Apr-20 12:00pm GMT

Wed, 17 Jun 2020 14:29:48 Q4 2020 ABIOMED Inc Earnings Call... Read Full Article

ABIOMED Unveils Digital Platform CAMP PCI for CAD Treatment

Wed, 17 Jun 2020 10:28:10 ABIOMEDand's (ABMD) new digital platform helps to deliver better patient outcomes for those suffering from CAD.... Read Full Article
<